Ridding the human body of HIV

Dec 02, 2010 By Erin White

A new Northwestern Medicine study will undertake a bold new protocol to completely eradicate latent HIV cells that current drugs don't affect. Participants, with diagnosed HIV, in the experimental group will be given an investigational HIV vaccine that actually wakes up dormant cells at the same time regular HIV-drug therapy is aimed at extinguishing the activated cells.

“If we can effectively decrease the reservoir then we can think about curing ," said Robert Murphy, M.D., founding director of Northwestern University Feinberg School of Medicine’s Center for Global Health and an infectious disease physician at Northwestern Memorial Hospital.

Many people with HIV are living with nearly undetectable levels of the virus in their blood, but they can’t entirely clear HIV out of their bodies with the current treatment regimens. Dormant HIV cells linger, hiding in the body and resisting the powerful benefits of anti-HIV drugs. Through the study, called EraMune 02, researchers at Feinberg’s Center for Global Health plan to activate dormant HIV cells, fight them off and kill the virus.

The first participant in the study was enrolled at Northwestern Medicine this week. The study will ultimately enroll and study 28 already HIV-infected participants in Chicago, New York and San Francisco for more than one year. A similar study, EraMune 01, also is taking place in Europe and includes participants from France, Spain, Italy and England.

“There is a reservoir of dormant, latently infected cells that current drugs don’t affect, and we think we now have drugs available that can actually attack the virus in the reservoir,” said Murphy, the principal investigator of the study and John Philip Phair professor of infectious diseases at Feinberg.

All participants will be given intensified doses of anti-HIV drugs for two months. Intensified drug therapy can suppress the amount of HIV in the blood to very low levels. Then participants will be randomly assigned (50/50) to either a control or an experimental group. In addition to the intensified HIV therapy, the experimental group will receive an investigational . In previous studies this vaccine has been shown to activate latently infected HIV cells.

“If you activate those cells in the presence of giving regular HIV-drug therapy, which would control and fight the virus, you might be able to extinguish the reservoir,” Murphy said.

After the treatment phase researchers will follow the participants for one year. They will study the white blood cells of the participants and measure the amount of HIV in the integrated DNA of the cells. This is the first in a series of studies that will examine the effect the intensified treatment and the vaccine have on the reservoir of latent HIV cells, Murphy said.

“We think it is a step in the right direction to find the immunologic agent that will eradicate the reservoir,“ Murphy said.

Explore further: Indiana HIV outbreak, hepatitis C epidemic sparks US alert

Related Stories

Exhausted B cells fail to fight HIV

Jul 14, 2008

HIV tires out the cells that produce virus-fighting proteins known as antibodies, according to a human study that will be published online July 14 in the Journal of Experimental Medicine.

Waking up dormant HIV

Mar 16, 2009

HAART (highly active anti-retroviral therapy) has emerged as an extremely effective HIV treatment that keeps virus levels almost undetectable; however, HAART can never truly eradicate the virus as some HIV always remains ...

Exhausted B cells hamper immune response to HIV

Jul 14, 2008

Recent studies have shown that HIV causes a vigorous and prolonged immune response that eventually leads to the exhaustion of key immune system cells--CD4+ and CD8+ T-cells--that target HIV. These tired cells become less ...

How HIV vaccine might have increased odds of infection

Nov 03, 2008

In September 2007, a phase II HIV-1 vaccine trial was abruptly halted when researchers found that the vaccine may have promoted, rather than prevented, HIV infection. A new study by a team of researchers at the Montpellier ...

Bone marrow can harbor HIV-infected cells (w/ Video)

Mar 07, 2010

University of Michigan scientists have identified a new reservoir for hidden HIV-infected cells that can serve as a factory for new infections. The findings, which appear online March 7 in Nature Medicine, indicate a new ...

A cure for HIV could be all in the 'mix'

Aug 18, 2010

Current HIV treatments do not eradicate HIV from host cells but rather inhibit virus replication and delay the onset of AIDS. However, a new research published in BioMed Central's open access journal, AIDS Research & Therapy descri ...

Recommended for you

Indiana HIV outbreak, hepatitis C epidemic sparks US alert

Apr 24, 2015

Federal health officials helping to contain an HIV outbreak in Indiana state issued an alert to health departments across the U.S. on Friday, urging them to take steps to identify and track HIV and hepatitis C cases in an ...

Why are HIV survival rates lower in the Deep South than the rest of the US?

Apr 22, 2015

The Deep South region has become the epicenter of the US HIV epidemic. Despite having only 28% of the total US population, nine states in the Deep South account for nearly 40% of national HIV diagnoses. This region has the highest HIV diagnosis rates and the highest number of people living with HIV of any ...

A bad buzz: Men with HIV need fewer drinks to feel effects

Apr 20, 2015

Researchers at Yale and the VA Pittsburgh Healthcare System compared the number of drinks that men with HIV infection, versus those without it, needed to get a buzz. They found that HIV-infected men were more sensitive to ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.